Category - Developments

Developments

Ondine presents effective photodisinfection treatment research against MRSA

Ondine Biomedical (LON:OBI) presented new research at the Infection Prevention Society Conference in Bournemouth, UK showing that its Steriwave photodisinfection technology is highly effective against clinical MRSA...

October 19, 2022

Developments

LENZ Therapeutics posts positive Phase 2 presbyopia treatment data

Closely held LENZ Therapeutics reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia, or farsightedness. Both LNZ100 (aceclidine)...

October 18, 2022

Developments

Comera reports favorable preclinical results of lead SQore excipient

Comera Life Sciences (NASDAQ:CMRA) reported favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study. the preclinical results showed that Comera’s caffeine-based SQore...

October 18, 2022

Developments

IntelGenx submits response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx (TSX:IGX; OTCQB:IGXT) responded to the complete response letter (CRL) for its 505(b)(2) NDA for RIZAPORT VersaFilm received from the FDA in March 2020. “We have been encouraged by our interactions with...

October 18, 2022

Developments

TIAP and Evotec expand LAB150 BRIDGE partnership to Include Amgen

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO; FSE: EVT) have expanded LAB150, their translational BRIDGE partnership, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion...

October 17, 2022

Developments

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

IntelGenx (TSX:IGX; OTCQB:IGXT) updated its collaboration with strategic partner, atai Life Sciences (NASDAQ:ATAI), which has begun a first-in-human Phase 1 study for the development of novel formulations of...

October 13, 2022

Developments

Sigyn Therapeutics to register ChemoPrep and ChemoPure as trademarks for devices to enhance cancer therapy

Sigyn Therapeutics (OTCQB:SIGY) disclosed that trademark applications to register ChemoPrep and ChemoPure have been filed with the United States Patent and Trademark Office (USPTO). The intent-to-use trademark...

October 13, 2022

Developments

Ripple Therapeutics signs licensing agreement for China with CS Pharmaceuticals

Closely held Ripple Therapeutics signed an exclusive licensing agreement for the Chinese rights to its lead product, IBE-814, with CS Pharmaceuticals, a British-based company focused on the development and...

October 11, 2022

Developments

Oramed unit posts positive preliminary Phase 1 oral COVID-19 vaccine data

Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) subsidiary, Oravax Medical, reported positive preliminary data from its Phase 1 trial of an oral COVID-19 vaccine candidate. Oravax Medical is developing oral vaccines that...

October 7, 2022

Developments

FDA clears Boston Cell Standards’ IHControls panel in breast cancer

Closely held Boston Cell Standards received 510(k) clearance from the FDA for its IHControls panel (HER2/ER/PR) for evaluating breast cancers, representing a first-in-category regulatory approval. IHControls are the...

October 6, 2022

Category - Developments

Subscribe